Skip to main content
. Author manuscript; available in PMC: 2022 Dec 22.
Published in final edited form as: Sci Transl Med. 2022 Jun 22;14(650):eabo4474. doi: 10.1126/scitranslmed.abo4474

Fig. 1. Study design.

Fig. 1.

PLS-NAFLD was derived in a cohort of patients with history of prior NAFLD-associated HCC who underwent curative ablation therapies and validated in HCC-naïve and HCC-experienced patients with NAFLD. PLS-NAFLD was translated to serum protein-based PLSec-NAFLD and validated in an independent cohort of HCC-naïve patients with cirrhosis from NAFLD.